|
Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Polyphor |
|
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; PharmaMar; Roche/Genentech; Taiho Pharmaceutical |
Research Funding - Novartis (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Celgene; Pierre Fabre; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Lilly; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche |
Speakers' Bureau - Lilly; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
Jose Alejandro Perez-Fidalgo |
Speakers' Bureau - AstraZeneca Spain; Ipsen; Novartis; Pfizer; PharmaMar; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche |
|
|
|
Stock and Other Ownership Interests - Celgene (I) |
Consulting or Advisory Role - Novartis |
Travel, Accommodations, Expenses - Novartis; Roche |
|
|
Honoraria - Advance Medical; Best Doctors, Inc; Cardinal Health |
Consulting or Advisory Role - AstraZeneca; Eisai; Immunomedics; Jounce Therapeutics |
Research Funding - Abbvie (Inst); Immunomedics (Inst); NeoImmuneTech (Inst); Pfizer (Inst); Polyphor (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Cardinal Health; Eisai; Immunomedics; Jounce Therapeutics; Odonate Therapeutics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Genentech; GlaxoSmithKline; Immunomedics; Lilly; Macrogenics; Novartis |
Research Funding - Genentech (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - Genentech; Macrogenics; Pfizer |
Speakers' Bureau - Genentech/Roche; Novartis; Pfizer; Tempus |
Research Funding - Seagen (Inst) |
|
|
Consulting or Advisory Role - Roche |
Speakers' Bureau - Pierre Fabre; Roche |
Travel, Accommodations, Expenses - Pierre Fabre; Roche |
|
|
Consulting or Advisory Role - Berg Pharma |
|
Research Funding - Abbvie (Inst); AstraZeneca (Inst); celldex (Inst); Clovis Oncology (Inst); Galena Biopharma (Inst); Immunomedics (Inst); millennium (Inst); Optimer Biotechnology (Inst); PharmaMar (Inst); Polyphor (Inst) |
Patents, Royalties, Other Intellectual Property - we have a patent pending on the application for BMD progenitor cells (Inst) |
|
|
|
|
Stock and Other Ownership Interests - Novartis; Polyphor |
|
|
|
Stock and Other Ownership Interests - Polyphor |
Patents, Royalties, Other Intellectual Property - Polyphor |
Travel, Accommodations, Expenses - Polyphor |
|
|
Stock and Other Ownership Interests - MedSIR |
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche; Samsung |
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Daiichi Sankyo; ERYTECH Pharma; Merus; Polyphor; Roche; Seagen |
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Pique (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer; Roche |